Evaluating the cost-utility of intravesical bacillus calmette-guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Kristin Grabe-HeyneChristof HenneIsaac OdeyemiJohannes PöhlmannWaqas AhmedRichard F PollockPublished in: Journal of medical economics (2023)
Intravesical BCG led to increased QALY and reduced costs versus RC for patients with high-risk NMIBC from the UK healthcare payer perspective.